Determination of a dosage regimen of colistin by pharmacokinetic/pharmacodynamic integration and modeling for treatment of G.I.T. disease in pigs

Guyonnet, J.; Manco, B.; Baduel, L.; Kaltsatos, V.; Aliabadi, M.H.F.S.; Lees, P.

doi:10.1016/j.rvsc.2009.09.001

Cited by 36 publications

(38 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike for human medicine, only a few studies have been conducted in pigs to evaluate the PK of colistin following oral (Guyonnet et al, 2010; Rhouma et al, 2015, 2016b) or intramuscular (IM) administration (Lin et al, 2005; Tang et al, 2009; He et al, 2011; Table 1 ). These studies were performed using CS, since this is the only form of colistin approved in swine medicine, and were conducted in healthy pigs.…”

Section: Pharmacokinetics and Pharmacodynamics (Pk And Pd) Of Colistimentioning

confidence: 99%

“…It is reasonable to think that the PK can be different in sick animals. The oral CS PK data in pigs were obtained using either a high-pressure liquid chromatography (HPLC) assay (Guyonnet et al, 2010) or a LC coupled with the tandem mass spectrometry (HPLC–MS/MS) method (Rhouma et al, 2015, 2016b). CS PK data in pigs after parenteral administration were obtained using mostly microbiological assays (Lin et al, 2005; Tang et al, 2009; Table 1 ); these data should be viewed with caution because of the limited sensitivity of this method and the descriptions of the experiment conditions.…”

Section: Pharmacokinetics and Pharmacodynamics (Pk And Pd) Of Colistimentioning

confidence: 99%

“…After oral CS administration in pigs and despite the use of a very sensitive analytical method, CS plasma concentrations were very difficult to quantify in healthy pigs (Guyonnet et al, 2010; Rhouma et al, 2015). A concurrent oral challenge of pigs with an ETEC: F4 strain did not increase CS intestinal absorption in a subclinical induction model of post-weaning diarrhea (PWD) (Rhouma et al, 2015).…”

Section: Pharmacokinetics and Pharmacodynamics (Pk And Pd) Of Colistimentioning

confidence: 99%

“…Colistin sulfate is the only form of colistin approved in pig production in some countries for the control of Enterobacteriaceae infections, particularly for those caused by Escherichia coli (Guyonnet et al, 2010; Rhouma et al, 2016a). Since its introduction on the market in the 60s, colistin was used in pig production in several countries with different purposes; therapeutically, prophylactically, and even for growth promotion (Katsunuma et al, 2007; Rhouma et al, 2016a).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives

et al. 2016

View full text Add to dashboard Cite

Colistin (Polymyxin E) is one of the few cationic antimicrobial peptides commercialized in both human and veterinary medicine. For several years now, colistin has been considered the last line of defense against infections caused by multidrug-resistant Gram-negative such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Colistin has been extensively used orally since the 1960s in food animals and particularly in swine for the control of Enterobacteriaceae infections. However, with the recent discovery of plasmid-mediated colistin resistance encoded by the mcr-1 gene and the higher prevalence of samples harboring this gene in animal isolates compared to other origins, livestock has been singled out as the principal reservoir for colistin resistance amplification and spread. Co-localization of the mcr-1 gene and Extended-Spectrum-β-Lactamase genes on a unique plasmid has been also identified in many isolates from animal origin. The use of colistin in pigs as a growth promoter and for prophylaxis purposes should be banned, and the implantation of sustainable measures in pig farms for microbial infection prevention should be actively encouraged and financed. The scientific research should be encouraged in swine medicine to generate data helping to reduce the exacerbation of colistin resistance in pigs and in manure. The establishment of guidelines ensuring a judicious therapeutic use of colistin in pigs, in countries where this drug is approved, is of crucial importance. The implementation of a microbiological withdrawal period that could reduce the potential contamination of consumers with colistin resistant bacteria of porcine origin should be encouraged. Moreover, the management of colistin resistance at the human-pig-environment interface requires the urgent use of the One Health approach for effective control and prevention. This approach needs the collaborative effort of multiple disciplines and close cooperation between physicians, veterinarians, and other scientific health and environmental professionals. This review is an update on the chemistry of colistin, its applications and antibacterial mechanism of action, and on Enterobacteriaceae resistance to colistin in pigs. We also detail and discuss the One Health approach and propose guidelines for colistin resistance management.

show abstract

Section: Pharmacokinetics and Pharmacodynamics (Pk And Pd) Of Colistimentioning

confidence: 99%

Section: Pharmacokinetics and Pharmacodynamics (Pk And Pd) Of Colistimentioning

confidence: 99%

Section: Pharmacokinetics and Pharmacodynamics (Pk And Pd) Of Colistimentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives

et al. 2016

View full text Add to dashboard Cite

show abstract

“…As a consequence, high concentrations are reached in the gastrointestinal tract. When given in line with the common therapeutic regimen recommended in Europe, colistin concentrations in faeces reach steady-state levels of about 60 µg/g in pigs (Kempf and others 2013, Fleury and others 2015), whereas peak levels of about 90 µg/g are reached after a single bolus oral administration (Guyonnet and others 2010). Guyonnet and others showed by pharmacokinetic/pharmacodynamic modelling that local (gut) bactericidal activity against bacterial strains with an MIC of 1 µg/ml will be obtained with oral doses of 2804 iu/kg bodyweight/day whereas bacterial eradication would be obtained at 11,679 iu/kg bodyweight.…”

mentioning

confidence: 99%